SHENZHEN, China, April 14, 2011 /PRNewswire-Asia/ -- Global Pharm Holdings Group, Inc. (OTC Bulletin Board: GPHG) ('Global Pharm" or the "Company"), a Shenzhen-based, leading vertically integrated pharmaceutical company engaged in pharmaceutical related products distribution business through its subsidiaries in Anhui, Jilin, and Shandong provinces, today reported financial results for the twelve months ended December 31, 2010.
Fiscal Year 2010 Highlights Revenues increased 61.7% year-over-year to $140.3 millionGross profit increased 64.5% year-over-year to $26.4 million with gross margin of 18.8% Operating income increased 12.3% year-over-year to $15.9 millionNet income was $11.2 million, or $0.51 per diluted share, as compared to $10.9 million, or $0.57 per diluted share, in the same period last yearAdjusted net income, which excluded non-cash expenses related to share-based compensation for employees and merger costs, was $17.9 million, or $0.82 per diluted share
"We are pleased to announce record financial results for 2010, which continues to validate our strategy of building a solid distribution capacity and growing to become a major rapid-growing and profitable pharmaceutical company," stated Mr. Yunlu Yin, Chief Executive Officer of Global Pharm.
Fiscal Year 2010 ResultsTotal Revenues for the twelve months ended December 31, 2010 increased by 61.7% to $140.3 million from $86.8 million in twelve months ended December 31, 2009.
The strong year-over-year revenue growth was mainly attributable to increased sales in the Company's pharmaceutical products distribution business segment, which grew 65.0% year-over-year, and the herbal cultivation and sales business segment, which grew 105.2% year-over year.
Below is a breakdown of sales per business segment for fiscal year 2010 a
Page: 1 2 3 4 5 6 7 8 9 Related biology technology :1
|SOURCE Global Pharm Holdings Group, Inc.|
Copyright©2010 PR Newswire.
All rights reserved
. The American Chamber of Commerce in Spain Awards the Global Business Leader Award 2011 to Victor Grifols Roura, President and CEO of Grifols2
. Tibotec Advances Global Clinical Research Program for TMC435 in HCV; Will Present Four Abstracts Evaluating Safety and Efficacy at EASL3
. Reportlinker Adds Quantum Dots: Technologies and Global Markets4
. Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry5
. Reportlinker Adds Global Nanobiotechnology Industry6
. Reportlinker Adds Global Biochips Industry7
. Top 5 Global Pharmaceutical Company Selects NewCardios QTinno for 2 Upcoming Phase I Drug Safety Trials8
. Global Growth Factors ( Blood And Tissue ) Industry9
. Global HPLC Systems & Accessories Industry10
. Global Specialty Enzymes Industry11
. BioNeutral Enters into Global Sales and Distribution Agreement with Raymond Associates to Expand Market for Military-Grade Ygiene(TM)